Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
Joel Liederman
1. Challenges Facing Early Stage Medical Technology Companies IVEY Medical Technology Innovation Symposium June 10, 2011 Presentation by Joel Liederman, Vice President
5. MaRS Innovation is a Network Centre of Excellence - Centre of Excellence in Commercialization and Research We have an initial 5 year mandate - $15M Federal Government & $10M from Members Building Next Generation Start-Ups in Ontario Improving Commercialization Output from Members (Universities & Hospitals) MaRS Innovation is Different from MaRSDD
6. Logistics Sourcing & Screening Opportunity Assessment Commercial Launch Start-ups Licensing Research Partnerships Marketplace Industry Partners Angels VCs SMEs Research Collaborations MaRS Innovation Member Institution’s TTO’s disclose ALL Invention disclosures – Dec 1, 2008
7.
8. Academic Environment: Scientific Publications & Citations Source: Science & Engineering Indicators 2006, US NSF; OCS Publications in leading LS Journals* per capita * Nature, Science, The Cell
9. Innovation: Canada is 8th in Med. Dev., 7 th in Biopharma Source: USPTO analysis by ILSI
10.
11. Risk Management Perspective Companies need to understand, plan for, and manage the risks that they face Technology Risk Market Risk Execution Risk
12.
13.
14.
15. The Financing Gap in Canada Time Low Investment & Risk Sales Low High High Risk Sales Investment MaRS Innovation Grants Angels Technology Start-up Growth Expansion Public Markets Gap Venture Capital
Inadequate support at the earliest stages of commercialization means that many Canadian discoveries are not transitioning to the culture of commerce. Infrastructure funding has been primarily dedicated to basic research and not on product development.
![Who is MaRS Innovation? ,[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)